IL153560A0 - Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer - Google Patents

Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Info

Publication number
IL153560A0
IL153560A0 IL15356001A IL15356001A IL153560A0 IL 153560 A0 IL153560 A0 IL 153560A0 IL 15356001 A IL15356001 A IL 15356001A IL 15356001 A IL15356001 A IL 15356001A IL 153560 A0 IL153560 A0 IL 153560A0
Authority
IL
Israel
Prior art keywords
farnesyl transferase
transferase inhibiting
quinoline enantiomer
annelated quinoline
annelated
Prior art date
Application number
IL15356001A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL153560A0 publication Critical patent/IL153560A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15356001A 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer IL153560A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (1)

Publication Number Publication Date
IL153560A0 true IL153560A0 (en) 2003-07-06

Family

ID=8171675

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15356001A IL153560A0 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
IL153560A IL153560A (en) 2000-06-22 2002-12-19 (-) - 5– (3 – chlorophenyl) - a– (4– chlorophenyl) - a– (1– methyl– H1 – imidazol – 5 – il) –tetrazolo [5,1– a] quinazoline – 7 – methanol as a drug Anti-arthropic and anti-inflammatory

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL153560A IL153560A (en) 2000-06-22 2002-12-19 (-) - 5– (3 – chlorophenyl) - a– (4– chlorophenyl) - a– (1– methyl– H1 – imidazol – 5 – il) –tetrazolo [5,1– a] quinazoline – 7 – methanol as a drug Anti-arthropic and anti-inflammatory

Country Status (33)

Country Link
US (3) US20030114471A1 (enExample)
EP (1) EP1296984B1 (enExample)
JP (1) JP4919575B2 (enExample)
KR (2) KR100831940B1 (enExample)
CN (1) CN1207296C (enExample)
AR (1) AR030704A1 (enExample)
AT (1) ATE294804T1 (enExample)
AU (3) AU2001263962B2 (enExample)
BG (1) BG65894B1 (enExample)
BR (1) BRPI0111743B8 (enExample)
CA (1) CA2410232C (enExample)
CZ (1) CZ295278B6 (enExample)
DE (1) DE60110592T2 (enExample)
EA (1) EA005065B1 (enExample)
EE (1) EE04966B1 (enExample)
EG (1) EG24180A (enExample)
ES (1) ES2241830T3 (enExample)
HR (1) HRP20020989B1 (enExample)
HU (1) HU229095B1 (enExample)
IL (2) IL153560A0 (enExample)
IS (1) IS2596B (enExample)
JO (1) JO2361B1 (enExample)
MX (1) MXPA02012845A (enExample)
MY (1) MY127734A (enExample)
NO (1) NO324494B1 (enExample)
NZ (1) NZ522481A (enExample)
PA (1) PA8519501A1 (enExample)
PL (1) PL209521B1 (enExample)
SA (1) SA01220349B1 (enExample)
SK (1) SK285699B6 (enExample)
UA (1) UA73572C2 (enExample)
WO (1) WO2001098302A1 (enExample)
ZA (1) ZA200210305B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
CA2481480C (en) 2002-04-15 2011-04-12 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
JP2017536403A (ja) * 2014-12-04 2017-12-07 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． デルタ肝炎ウイルス感染の治療
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
US10471055B2 (en) 2015-08-17 2019-11-12 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
HRP20210544T1 (hr) 2016-11-03 2021-08-20 Kura Oncology, Inc. Inhibitori farneziltransferaze za uporabu u liječenju raka

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
DE69635966T2 (de) * 1995-12-08 2006-11-30 Janssen Pharmaceutica N.V. (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren
CA2249615A1 (en) 1996-04-03 1997-10-09 Robert Gomez Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
SK146199A3 (en) * 1997-04-25 2000-06-12 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
IL133212A (en) 1997-06-02 2005-12-18 Janssen Pharmaceutica Nv History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
ID26987A (id) * 1998-07-06 2001-02-22 Janssen Pharmaceutica Nv Inhibitor-inhibitor transferase protein farnesil dengan sifat-sifat peka terhadap sinar radiasi in vivo
CA2341739C (en) * 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
KR20010072991A (ko) * 1998-08-27 2001-07-31 실버스타인 아써 에이. 항암제로서 유용한 알키닐-치환된 퀴놀린-2-온 유도체
PT1140935E (pt) * 1998-12-23 2003-10-31 Janssen Pharmaceutica Nv Derivados da quinolina 1,2-ciclizada
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
TR200201296T2 (tr) * 1999-02-11 2002-07-22 Pfizer Products Inc. Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
JP2003523381A (ja) 2000-02-24 2003-08-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 投与レジメン
JP4974439B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体
ATE409189T1 (de) 2000-09-25 2008-10-15 Janssen Pharmaceutica Nv Farnesyl transferase-hemmende 6- heterocyclylmethyl-chinolin und chinazol-derivate

Also Published As

Publication number Publication date
HK1058363A1 (en) 2004-05-14
EE200200695A (et) 2004-06-15
CZ295278B6 (cs) 2005-06-15
EA005065B1 (ru) 2004-10-28
AU2001263962B2 (en) 2006-07-20
CA2410232C (en) 2008-10-07
DE60110592D1 (de) 2005-06-09
JP2004501153A (ja) 2004-01-15
BRPI0111743B8 (pt) 2021-05-25
US8318753B2 (en) 2012-11-27
EE04966B1 (et) 2008-02-15
HUP0300872A3 (en) 2004-11-29
CA2410232A1 (en) 2001-12-27
SK502003A3 (en) 2003-05-02
BR0111743A (pt) 2003-07-08
JP4919575B2 (ja) 2012-04-18
NO20026032L (no) 2002-12-16
ES2241830T3 (es) 2005-11-01
HRP20020989B1 (hr) 2011-05-31
AU2006220405A1 (en) 2006-10-12
BRPI0111743B1 (pt) 2019-03-26
HUP0300872A2 (hu) 2003-07-28
BG65894B1 (bg) 2010-04-30
JO2361B1 (en) 2006-12-12
SA01220349B1 (ar) 2007-01-23
PL358918A1 (en) 2004-08-23
KR100846370B1 (ko) 2008-07-15
EG24180A (en) 2008-09-28
NO324494B1 (no) 2007-10-29
HRP20020989A2 (en) 2005-02-28
CZ2003114A3 (cs) 2003-05-14
IS6590A (is) 2002-10-25
CN1437601A (zh) 2003-08-20
NO20026032D0 (no) 2002-12-16
AR030704A1 (es) 2003-09-03
PA8519501A1 (es) 2002-08-29
PL209521B1 (pl) 2011-09-30
EA200300048A1 (ru) 2003-04-24
KR20070121847A (ko) 2007-12-27
NZ522481A (en) 2004-09-24
ATE294804T1 (de) 2005-05-15
DE60110592T2 (de) 2006-01-19
AU6396201A (en) 2002-01-02
BG107310A (bg) 2003-07-31
HU229095B1 (en) 2013-07-29
US20030114471A1 (en) 2003-06-19
UA73572C2 (en) 2005-08-15
MXPA02012845A (es) 2003-05-15
US20070259902A1 (en) 2007-11-08
KR20030009463A (ko) 2003-01-29
KR100831940B1 (ko) 2008-05-23
IS2596B (is) 2010-03-15
CN1207296C (zh) 2005-06-22
EP1296984B1 (en) 2005-05-04
US8329714B2 (en) 2012-12-11
EP1296984A1 (en) 2003-04-02
AU2006220405B2 (en) 2009-05-21
ZA200210305B (en) 2004-03-19
WO2001098302A1 (en) 2001-12-27
MY127734A (en) 2006-12-29
US20080114009A1 (en) 2008-05-15
IL153560A (en) 2011-06-30
SK285699B6 (sk) 2007-06-07

Similar Documents

Publication Publication Date Title
GB2375785C (en) Subsea intervention
TW429766U (en) Improved pressure pot
AU4787301A (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
IL155679A0 (en) Antimicrobial quinolones
ZA200007669B (en) Insert.
AU2001293835A1 (en) Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
AU2679401A (en) Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives
MXPA03005673A (es) Inhibidores de 8-arilquinolin-fosfodiesterasa-4-substituidos.
AU6396201A (en) Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
NO20032471D0 (no) Farnesyltransferaseinhibitorer
EP1056450A4 (en) FARNESYL PROTEIN TRANSFERASE INHIBITORS
IL162310A0 (en) 3,4-Dihydro-1h-isoquinoloin-2-yl-derivatives
PL355887A1 (en) Farnesyl transferase inhibitors
GB2398613B (en) Improved permanently fixable plug
MXPA03004878A (es) Nuevos inhibidores de la transferasa de la proteina farnesilo.
HU0100747D0 (en) Raney cuprum
GB2365890B (en) Multiple bore christmas tree outlet
PL344820A1 (en) Distributor
GB0123593D0 (en) Improved 13 amp plug
TW545805U (en) Improved equalized distributor
CA92310S (en) Christmas tree holder
GB0014548D0 (en) Boiler brain
HK1047742A (en) Farnesyl transferase inhibitors
GB0005172D0 (en) Spindler 2000
PL111283U1 (en) Hanger